Low-dose anticoagulation therapy can be used safely with new design mechanical heart valve

May 15, 2014

Less aggressive anticoagulation therapy, combined with low-dose aspirin, can be used safely in conjunction with a newer generation mechanical heart valve. These findings from the first phase of a randomized clinical trial are published in The Journal of Thoracic and Cardiovascular Surgery, an official publication of the American Association for Thoracic Surgery.

Patients under 65 years of age requiring heart have had to choose between a mechanical valve that may last a lifetime but requires aggressive anti-clotting treatment with warfarin, and a biological (cow or pig) valve that does not require warfarin treatment but will need replacement in 10-20 years. Aggressive anti-clotting treatment is accompanied by significant risk of bleeding, while inadequate treatment can result in an increased incidence of stroke.

Therefore, the choice between valve types for physicians and narrows to one of avoidance of the risk, pain, and costs of reoperation for valve obsolescence versus avoidance of the lifetime composite risk of bleeding and thromboembolism and the nuisance of ongoing anticoagulation management. Both valve types can develop complications which, although rare, can result in reoperation, stroke, or death.

The US Food and Drug Administration (FDA) approved a randomized trial to test the safety of less aggressive anti-clotting treatment than the American Heart Association/American College of Cardiology guidelines currently recommend, in patients implanted with a newer generation On-X heart valve. "This is a bileaflet approved by the FDA, which is designed to function with less anticoagulation, or in some cases, antiplatelet therapy only," explains John D. Puskas, MD, Professor of Cardiothoracic Surgery at the Icahn School of Medicine at Mount Sinai, and Chairman of the Department of Cardiothoracic Surgery, Mount Sinai Beth Israel, New York, NY.

In this first phase of the three-phase Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT), conducted under an FDA investigational device exemption, 375 aortic valve replacement patients with elevated risk factors for clotting were randomized into control (190) and test (185) groups from September 2006 to December 2009 at 33 US centers. Patients in the control group received standard treatment of warfarin to maintain a target range of the International Normalized Ratio (INR) of 2.0-3.0. Patients in the treatment group received low-dose warfarin, targeting an INR of 1.5-2.0, after an initial 90 postoperative days of standard therapy. All patients received 81 mg aspirin daily.

The patients were followed up by in-person visits at three months, six months, and one year after surgery and then annually for between five and eight postoperative years to accrue the necessary 800 patient-years of follow-up mandated by the FDA. During these visits, electrocardiography or echocardiography was performed as required by the protocol and as clinically indicated. All patients maintained with warfarin therapy were followed up using weekly home INR testing through a central telephone or online database.

"The results show that anticoagulation may be safely reduced in patients following with this approved bileaflet mechanical prosthesis," says Dr. Puskas. "INR can be safely maintained between 1.5 and 2.0. With low-dose aspirin, this resulted in a significantly lower risk of bleeding, without a significant increase in thromboembolism. In high-risk recipients of On-X valves, the INR should be assiduously kept above 1.5 to maximize the safety and effectiveness of this therapeutic change," he concludes.

The investigators caution that results from the present trial should not be extrapolated to other prostheses, mechanical mitral valve replacements, or patients undergoing double aortic valve/mitral valve replacement. The present standard of care for all mechanical AVR patients outside the PROACT study remains conventional anticoagulation, as indicated by the American Heart Association/American College of Cardiology guidelines.

Two further phases of PROACT are planned. The second will be used to compare current anticoagulant therapy versus aspirin and/or clopidogrel only in selected lower risk patients requiring atrial valve replacement. The third will compare standard anticoagulation therapy versus INR goal of 2 to 2.5 in patients requiring mitral valve replacement.

Explore further: Low-dose anticoagulation therapy used with new design mechanical heart valve lowers bleeding risk

More information: "Reduced anticoagulation after mechanical aortic valve replacement: Interim results from the Prospective Randomized On-X Valve Anticoagulation Clinical Trial randomized Food and Drug Administration investigational device exemption trial," by John Puskas, MD, MSc, FACS, FACC; Marc Gerdisch, MD; Dennis Nichols, MD; Reed Quinn, MD; Charles Anderson, MD; Birger Rhenman, MD; Lilibeth Fermin, MD; Michael McGrath, MD; Bobby Kong, MD; Chad Hughes, MD; Gulshan Sethi, MD; Michael Wait, MD; Tomas Martin, MD; and Allen Graeve, MD, on behalf of all PROACT Investigators (DOI: dx.doi.org/10.1016/j.jtcvs.2014.01.004), The Journal of Thoracic and Cardiovascular Surgery, Volume 147, Issue 4.

Related Stories

Low-dose anticoagulation therapy used with new design mechanical heart valve lowers bleeding risk

May 6, 2013
For more than 40 years, patients under 65 years of age requiring heart valve replacement have had to choose between a mechanical valve that offers life-long durability but requires aggressive warfarin anticoagulation or a ...

Repeat sternotomy for aortic valve replacement safe option for octogenarian patients

March 26, 2014
Surgical aortic valve replacement generally improves patients' symptoms and prolongs survival. However, the perceived risk of surgical aortic valve replacement in patients over 80 may result in surgery being denied or a recommendation ...

Blood thinner dangerous for patients with artificial heart valves, study finds

September 26, 2013
(HealthDay)—When used by patients with mechanical heart valves, the blood thinner Pradaxa raises the risk of both dangerous clots and bleeding around the heart, a new study says.

TAVI is safe alternative to redo cardiac surgery

September 2, 2013
TAVI is a safe alternative to redo cardiac surgery for failing bioprosthetic valves, according to research presented at the ESC Congress today by Dr. Spyridon Katsanos from the Netherlands. The findings suggest that transcatheter ...

Study examines anticoagulation treatment following aortic valve replacement

November 27, 2012
Although current guidelines recommend 3 months of anticoagulation treatment after bioprosthetic aortic valve replacement surgery, a study that included more than 4,000 patients found that patients who had warfarin therapy ...

Approval expanded for sapien artificial heart valve

October 22, 2012
(HealthDay)—U.S. Food and Drug Administration approval for the Sapien Transcatheter Heart Valve has been expanded to include additional people with aortic valve stenosis, the medical term for a narrowing of the aortic valve ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.